JP2021513997A5 - - Google Patents
Info
- Publication number
- JP2021513997A5 JP2021513997A5 JP2020544277A JP2020544277A JP2021513997A5 JP 2021513997 A5 JP2021513997 A5 JP 2021513997A5 JP 2020544277 A JP2020544277 A JP 2020544277A JP 2020544277 A JP2020544277 A JP 2020544277A JP 2021513997 A5 JP2021513997 A5 JP 2021513997A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- seq
- amino acid
- acid sequence
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023060944A JP2023089063A (ja) | 2018-02-21 | 2023-04-04 | Ｂ７－ｈ４抗体の投薬計画 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862633527P | 2018-02-21 | 2018-02-21 | |
| US62/633,527 | 2018-02-21 | ||
| US201962802100P | 2019-02-06 | 2019-02-06 | |
| US62/802,100 | 2019-02-06 | ||
| PCT/US2019/018963 WO2019165075A1 (en) | 2018-02-21 | 2019-02-21 | B7-h4 antibody dosing regimens |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023060944A Division JP2023089063A (ja) | 2018-02-21 | 2023-04-04 | Ｂ７－ｈ４抗体の投薬計画 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021513997A JP2021513997A (ja) | 2021-06-03 |
| JP2021513997A5 true JP2021513997A5 (enExample) | 2022-03-01 |
| JP7258038B2 JP7258038B2 (ja) | 2023-04-14 |
| JP7258038B6 JP7258038B6 (ja) | 2023-04-25 |
Family
ID=65686103
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020544277A Active JP7258038B6 (ja) | 2018-02-21 | 2019-02-21 | Ｂ７－ｈ４抗体の投薬計画 |
| JP2023060944A Pending JP2023089063A (ja) | 2018-02-21 | 2023-04-04 | Ｂ７－ｈ４抗体の投薬計画 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023060944A Pending JP2023089063A (ja) | 2018-02-21 | 2023-04-04 | Ｂ７－ｈ４抗体の投薬計画 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20210070862A1 (enExample) |
| EP (1) | EP3755719A1 (enExample) |
| JP (2) | JP7258038B6 (enExample) |
| KR (1) | KR102863169B1 (enExample) |
| CN (1) | CN111868089B (enExample) |
| AU (1) | AU2019226009B2 (enExample) |
| BR (1) | BR112020016990A2 (enExample) |
| CA (1) | CA3091161A1 (enExample) |
| IL (1) | IL276623A (enExample) |
| MA (1) | MA51902A (enExample) |
| MX (1) | MX2020008730A (enExample) |
| SG (1) | SG11202007820QA (enExample) |
| WO (1) | WO2019165075A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11306144B2 (en) * | 2017-08-25 | 2022-04-19 | Five Prime Therapeutics, Inc. | B7-H4 antibodies and methods of use thereof |
| BR112020016986A2 (pt) * | 2018-02-21 | 2021-03-02 | Five Prime Therapeutics, Inc. | formulações de anticorpo contra b7-h4 |
| KR20200144094A (ko) | 2018-03-02 | 2020-12-28 | 파이브 프라임 테라퓨틱스, 인크. | B7-h4 항체 및 이의 사용 방법 |
| KR20210076025A (ko) * | 2018-10-15 | 2021-06-23 | 파이브 프라임 테라퓨틱스, 인크. | 암 병용 요법 |
| MX2023008000A (es) | 2021-01-04 | 2023-07-13 | Mersana Therapeutics Inc | Conjugados de anticuerpo dirigido a b7-h4 y farmaco, y metodos de uso de los mismos. |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US6174666B1 (en) | 1992-03-27 | 2001-01-16 | The United States Of America As Represented By The Department Of Health And Human Services | Method of eliminating inhibitory/instability regions from mRNA |
| DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
| CA2704600C (en) | 1999-04-09 | 2016-10-25 | Kyowa Kirin Co., Ltd. | A method for producing antibodies with increased adcc activity |
| EP1229125A4 (en) | 1999-10-19 | 2005-06-01 | Kyowa Hakko Kogyo Kk | PROCESS FOR PREPARING A POLYPEPTIDE |
| ES2252261T3 (es) | 2000-06-28 | 2006-05-16 | Glycofi, Inc. | Metodos para producir glicoproteinas modificadas. |
| CA2424977C (en) | 2000-10-06 | 2008-03-18 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| CA2953239A1 (en) | 2000-10-06 | 2002-04-18 | Kyowa Hakko Kirin Co., Ltd. | Antibody composition-producing cell |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| NZ571596A (en) | 2001-08-03 | 2010-11-26 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| CN101613705A (zh) | 2002-03-19 | 2009-12-30 | 国际植物研究所 | 在植物中优化聚糖生成 |
| US20040014194A1 (en) | 2002-03-27 | 2004-01-22 | Schering Corporation | Beta-secretase crystals and methods for preparing and using the same |
| EP2248892B1 (en) | 2003-01-22 | 2015-04-22 | Roche Glycart AG | Fusion constructs and use of same to produce antibodies with increased FC receptor binding affinity and effector function |
| BRPI0611445A2 (pt) | 2005-05-09 | 2010-09-08 | Glycart Biotechnology Ag | molécula de ligação a antìgeno glicomanipulada, polinucleotìdeo, polipeptìdeo, vetor, célula hospedeira, método para produção, uso e composição farmacêutica |
| JP2009526520A (ja) | 2006-01-17 | 2009-07-23 | バイオレックス セラピュティックス インク | 植物中でのｎ−グリカンのヒト化及び最適化のための組成物及び方法 |
| US7846724B2 (en) | 2006-04-11 | 2010-12-07 | Hoffmann-La Roche Inc. | Method for selecting CHO cell for production of glycosylated antibodies |
| ES2692268T5 (en) | 2011-03-29 | 2025-02-26 | Roche Glycart Ag | Antibody fc variants |
| US9676854B2 (en) * | 2011-08-15 | 2017-06-13 | Medimmune, Llc | Anti-B7-H4 antibodies and their uses |
| CA2894879A1 (en) * | 2012-12-19 | 2014-06-26 | Amplimmune, Inc. | B7-h4 specific antibodies, and compositions and methods of use thereof |
| KR102516152B1 (ko) | 2013-08-01 | 2023-03-31 | 파이브 프라임 테라퓨틱스, 인크. | 비푸코실화된 항-ｆｇｆｒ２ｉｉｉｂ 항체 |
| CN107299085B (zh) * | 2017-05-26 | 2020-09-29 | 广东医科大学 | 分泌抗人b7-h4胞外单克隆抗体杂交瘤细胞株和抗人b7-h4单克隆抗体及其应用 |
| US11306144B2 (en) * | 2017-08-25 | 2022-04-19 | Five Prime Therapeutics, Inc. | B7-H4 antibodies and methods of use thereof |
-
2019
- 2019-02-21 CA CA3091161A patent/CA3091161A1/en active Pending
- 2019-02-21 JP JP2020544277A patent/JP7258038B6/ja active Active
- 2019-02-21 EP EP19709318.0A patent/EP3755719A1/en active Pending
- 2019-02-21 KR KR1020207026649A patent/KR102863169B1/ko active Active
- 2019-02-21 AU AU2019226009A patent/AU2019226009B2/en active Active
- 2019-02-21 WO PCT/US2019/018963 patent/WO2019165075A1/en not_active Ceased
- 2019-02-21 CN CN201980019155.0A patent/CN111868089B/zh active Active
- 2019-02-21 SG SG11202007820QA patent/SG11202007820QA/en unknown
- 2019-02-21 MX MX2020008730A patent/MX2020008730A/es unknown
- 2019-02-21 BR BR112020016990-0A patent/BR112020016990A2/pt not_active Application Discontinuation
- 2019-02-21 MA MA051902A patent/MA51902A/fr unknown
-
2020
- 2020-08-10 IL IL276623A patent/IL276623A/en unknown
- 2020-08-19 US US16/997,581 patent/US20210070862A1/en not_active Abandoned
-
2022
- 2022-09-27 US US17/935,805 patent/US20230287123A1/en not_active Abandoned
-
2023
- 2023-04-04 JP JP2023060944A patent/JP2023089063A/ja active Pending
-
2024
- 2024-06-12 US US18/741,328 patent/US20240317864A1/en active Pending